Prognosis of different irradiation methods in patients with T2-3N0M0 esophageal squamous cell carcinoma
10.3760/cma.j.issn.1004-4221.2020.01.004
- VernacularTitle: 不同放疗方式对T2-3N0M0期食管鳞癌患者预后分析
- Author:
Wenbin SHEN
1
;
Hongmei GAO
2
;
Shuchai ZHU
1
;
Yankun CAO
1
;
Shuguan LI
1
;
Jinrui XU
1
Author Information
1. Department of Radiation Oncology, Forth Hospital, Hebei Medical University, Shijiazhaung 050011, China
2. Department of Radiation, First Hospital of Shijiazhaung, Shijiazhaung 050011, China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasm/involved-field irradiation;
Esophageal neoplasm/elective node irradiation;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2020;29(1):17-21
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of different irradiation methods on the long-term prognosis of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, aiming to select the optimal treatment for these patients.
Methods:A total of 268 eligible patients admitted to our hospital from January 2007 to December 2012 were enrolled in this study. All patients were divided into the involved-field irradiation (IFI) and elective node irradiation (ENI) groups. The composition ratio, prognostic factors and adverse events were analyzed between two groups.
Results:The median overall survival (OS) time was 35.5 months (95%CI : 30.12-40.88) and the median disease-free survival (DFS) time was 23.5 months (95%CI: 19.00-28.00). According to the multivariate analysis results, all patients were assigned into two groups at a ratio of 1 vs.1(n=86 in each group). Multivariate analysis after propensity score matching (PSM) demonstrated that irradiation method was the independent factor of OS (P=0.038), and T stage and radiotherapy were the independent factors affecting DFS (P=0.002, 0.032). The incidence of ≥grade Ⅱ adverse events did not significantly differ between two groups (P=0.819, 0.756). However, patients with combined chemotherapy experienced more adverse events.
Conclusion:ENI can prolong the OS and DFS of patients with clinical T2-3N0M0 esophageal squamous cell carcinoma, and does not increase the incidence of severe adverse events.
